Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001342238 | SCV001536157 | likely benign | Episodic ataxia type 2; Developmental and epileptic encephalopathy, 42 | 2022-02-24 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002546954 | SCV003581732 | uncertain significance | Inborn genetic diseases | 2021-09-17 | criteria provided, single submitter | clinical testing | The c.3703C>T (p.R1235C) alteration is located in exon 22 (coding exon 22) of the CACNA1A gene. This alteration results from a C to T substitution at nucleotide position 3703, causing the arginine (R) at amino acid position 1235 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Gene |
RCV004727168 | SCV005335073 | uncertain significance | not provided | 2023-05-18 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 29991641) |
Ce |
RCV004727168 | SCV005433886 | uncertain significance | not provided | 2024-09-01 | criteria provided, single submitter | clinical testing | CACNA1A: PM2, PP2 |